Percutaneous Revascularization of Coronary Chronic Total Occlusions The New Era Begins⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology. by Thompson, Craig A.
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ercutaneous Revascularization
f Coronary Chronic
otal Occlusions
he New Era Begins*
raig A. Thompson, MD, MMSC
ew Haven, Connecticut
he best available current evidence suggests that the hard
nd point outcomes of patients with coronary chronic total
cclusion (CTO) are no different from those of patients
ith nonoccluded stenoses. The reassurance that these
esions are benign because they are “well collateralized” or
not at risk for closure” is not well-founded and contradic-
ory to a large body of evidence implying the opposite (1–6).
atients with attempted CTO percutaneous coronary inter-
ention (PCI) that is successful have improved survival
ompared with those with unsuccessful attempts and per-
istently closed arteries. In addition, successful PCI of CTO
s associated with improved quality of life, reduced ischemia,
nd improved regional and global left ventricular function
3,7–9). These benefits are predicated on persistent patency
f the PCI segment.
See page 143
The concept that “stable” coronary disease (a definition
rudely derived from patient symptomatic status) is a
niform phenotype and has predictable outcomes continues
o be challenged in the presence of data that suggest
oronary disease is not intrinsically stable but rather repre-
ents a risk continuum (10,11). In the highest-risk patients
ith multivessel coronary disease, incomplete revasculariza-
ion with and without presence of CTO seems to have
oorer survival compared with patients who can be com-
letely revascularized (12–14). One can only logically con-
lude that CTO is not a benign entity.
Differential outcomes of patients with single-vessel cor-
nary disease can be segregated by the degree of ischemic
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Yale University School of Medicine, New Haven, Connecticut. Dr.
hompson is an advisor and consultant for Abbott Vascular and Bridgepointi
edical and has received honoraria from Asahi Intec, Terumo Medical,
edtronic, Inc., and ev3.urden, which might help better discriminate those patients
ho could derive survival benefit from revascularization
10,11). Considering this, is seems reasonable to construct a
odel to triage patients for revascularization of occluded
rteries on the basis of ischemic risk assessment (Fig. 1),
ymptomatic status, and attributable impairment of left
entricular function. This ischemic risk model can help
econcile apparent conflicting recent data from the OAT
Occluded Artery Trial), which enrolled patients with
redominantly nonchronically occluded arteries (e.g., not
TO by conventional definition), after recent myocardial
nfarction with minimal residual ischemia and symptoms
15). Low-risk patients might be safely deferred, but higher-
isk patients with ischemic burden or symptoms should be
onsidered for revascularization. This model is strongly
upported by the COURAGE (Clinical Outcomes Utiliz-
ng Revascularization and Aggressive Drug Evaluation)
rial’s nuclear substudy (11). It is likely the magnitude of
enefit is underestimated, given that the COURAGE trial
equired coronary angiography before enrollment and there-
ore might have excluded higher-risk patients.
The CTO PCI attempt rates of patients identified are
elatively low (approximately 11% to 13%) and seem
nchanged over time during recent years (8). It is very
ikely that—when attributable symptoms of chest pain,
eart failure/dyspnea, and/or fatigue; left ventricular
ysfunction; and the risk continuum model (Fig. 1) are
onsidered—we are dramatically under-revascularizing
hese patients in terms of attempt rates in patients with
ppropriate indications.
A major reason for this is related to the technical
omplexity and poor success rates for CTO PCI procedures
approximately 50% to 70% in “less complex” CTO
esions) and concerns for adverse acute procedure-related
omplications. Coronary bypass is seen as an alternative for
atients with multivessel disease, but the widely held notion
hat this surgical procedure can uniformly provide successful
ypass grafting to the CTO segment or offer completed
evascularization in this patient subset has been refuted. The
nitial reports from the randomized SYNTAX (SYNergy
etween PCI With TAXUS and Cardiac Surgery) clinical
rial CTO subset suggest similar challenges are encountered
y our surgical colleagues with successful bypass grafting of
he CTO segment in only 69% and complete revasculariza-
ion in 49.6% in this complex patient/lesion subset (16).
tand-alone medical therapy as an alternative does not
educe ischemic burden and might be less preferable in
atients at highest risk.
The paper by Morino et al. (17) in this issue of JACC:
ardiovascular Interventions details a contemporary multi-
enter experience from 498 patients having CTO PCI in
he J-CTO registry (multicenter CTO Registry in Japan)
rom April 2006 to November 2007. Multiple operators and
nstitutions were capable of achieving high technical success
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15386.6%) with low rates of cardiac death (0.2%) and signif-
cant myocardial infarction (2.1%) with contemporary and
dvanced technical approaches, including contralateral in-
ection, parallel wiring, intravascular ultrasound guidance,
nd retrograde techniques (overall retrograde attempt in-
luded 25.7% of procedures). The technical success and
n-hospital outcomes compare very favorably and are con-
istent with similar contemporary experiences and limited
eports from the U.S. (approximately 90% technical success,
pproximately 2% major adverse cardiac events) and Europe
approximately 83.4% technical success, approximately 2%
ajor adverse cardiac events) in this timeframe (18,19). The
-CTO investigators did not discuss the operator’s and
nstitution’s experience level in the present report, but these
re presumed to be quite high, and therefore we do not
now the immediate applicability and reproducibility of
hese data to less experienced operators in Japan and
lsewhere in the world. However, cumulatively, these re-
orts demonstrate a potential pathway for high technical
uccess with low adverse event profile in widely disparate
linical and cultural environments, predicated on innovative
echniques pioneered in Japan and now continuing to be
terated throughout the world.
Yet, many coronary arteries causing patients symptoms
nd harm remain closed. How can these techniques and
esults best be translated in a broad manner to better impact
Figure 1. Ischemic Risk Model for Coronary Disease With Predictable/Stab
Current outcomes data suggest that adverse events for coronary disease can b
nary disease) and magnitude and degree of ischemia. In this revascularization
on the basis of predictable symptoms but rather as a risk continuum. In this m
syndromes, myocardial infarction, and death. The highest-risk patients seem to
revascularization are presumed to be greatest for patients with multivessel dis
artery (LAD) CTO, followed by single-vessel right coronary artery (RCA) or left c
represent a framework to substratify (in addition to symptomatic status) and d
coronary artery disease.ublic health? vFirst, identify patients appropriate for the procedure.
atients with symptoms or attributable left ventricular
mpairment in whom the risk-benefit estimate justifies the
rocedure should be considered for revascularization. In
atients (young or young elderly) with an otherwise long life
xpectancy, completed revascularization for multivessel dis-
ase, left anterior descending coronary artery CTO, and
on-left anterior descending coronary artery CTO with
arge ischemic burden should be considered, irrespective of
ymptomatic status. Patients with minimal symptoms and
schemia generally should be deferred.
Second, a broader access to operators performing CTO
CI is needed. In the absence of disruptive technologic
dvances, this would be best served in a multitiered system
here “simple” CTO PCI can be performed by less-
xperienced operators and prior PCI failures or more
omplex lesion/clinical populations be referred to a dedi-
ated “CTO specialist.” It is clear that the safety and
ffectiveness of the more complex strategies are related to
perator volume and ascension of a learning curve (18).
dequate training programs and continuing medical edu-
ation will need to continue to be developed to broaden the
ool of CTO operators.
Third, very few health care and reimbursement systems
alue the time and resource use that can be required for a
uccessful CTO PCI program. Currently, data are lacking
n cost-effectiveness, and current health care systems in
mptoms: A Decision Matrix for CTO Revascularization
-predicted by coronary disease burden (e.g., phenotyped multivessel coro-
on matrix model, coronary disease is not assumed to be intrinsically stable
patients at higher risk are more likely to destabilize and transition to acute
the greatest magnitude of beneﬁt from revascularization. Beneﬁts from
ith chronic total occlusion (CTO) and left anterior descending coronary
ﬂex artery (LCx) CTO with high ischemic burden. This risk continuum might
ine revascularization, including that for CTO, for patients with nonacutele Sy
e risk
decisi
odel,
have
ease w
ircum
etermarious countries impede rather than encourage CTO PCI
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154n favor of time- and resource-limited procedures. Adjust-
ents in reimbursement models aligned with CTO PCI
ould improve patient access to these procedures and
enefits.
The J-CTO investigators and other early leaders from
apan should be congratulated and acknowledged for tech-
ique innovations to improve the safety and effectiveness of
TO PCI, which now is slowly but surely being reproduced
nd iterated elsewhere in the world. On the basis of the
ollective emerging data, it seems that success rates of 80%
o 90% with the contemporary strategies and techniques are
onsistently achievable in experienced hands with a safety
rofile comparable to standard risk-adjusted PCI. The
ustifications and attitude to avoid CTO revascularization
n the basis of real or perceived poor success rates, unclear
atient benefits, adverse outcomes, time/resource use, or
eed for coronary bypass surgery are becoming part of our
ollective past. As these advances are disseminated, the new
ra of CTO revascularization in patients with symptoms
nd/or ischemic burden begins in which the question is not
Why should we open the occluded vessel?” but “What is
he justification to leave the vessel closed?”
eprint requests and correspondence: Dr. Craig A. Thompson,
ale University School of Medicine, PO Box 208016, 333 Cedar
treet, Fitkin 3, New Haven, Connecticut 06520. E-mail:
raig.Thompson@Yale.edu.
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